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 Injectable Colloidal Gold for Use in Intrafractional 
2D Image-Guided Radiation Therapy 
 Rasmus I.  Jølck ,  Jonas S.  Rydhög ,  Anders N.  Christensen ,  Anders E.  Hansen , 
 Linda M.  Bruun ,  Henrik  Schaarup-Jensen ,  Asger Stevner  von Wenck ,  Betina  Børresen , 
 Annemarie T.  Kristensen ,  Mads H.  Clausen ,  Andreas  Kjær ,  Knut  Conradsen , 
 Rasmus  Larsen ,  Per Munck  af Rosenschöld ,  and  Thomas L.  Andresen* 
DOI: 10.1002/adhm.201400651
 In the western world, approximately 50% of all cancer patients receive radio-
therapy alone or in combination with surgery or chemotherapy. Image-guided 
radiotherapy (IGRT) has in recent years been introduced to enhance precision 
of the delivery of radiation dose to tumor tissue. Fiducial markers are often 
inserted inside the tumor to improve IGRT precision and to enable monitor-
ing of the tumor position during radiation therapy. In the present article, a 
liquid fi ducial tissue marker is presented, which can be injected into tumor 
tissue using thin and fl exible needles. The liquid fi ducial has high radio-
opacity, which allows for marker-based image guidance in 2D and 3D X-ray 
imaging during radiation therapy. This is achieved by surface-engineering 
gold nanoparticles to be highly compatible with a carbohydrate-based gela-
tion matrix. The new fi ducial marker is investigated in mice where they are 
highly biocompatible and stable after implantation. To investigate the clinical 
potential, a study is conducted in a canine cancer patient with spontane-
ous developed solid tumor in which the marker is successfully injected and 
used to align and image-guide radiation treatment of the canine patient. It is 
concluded that the new fi ducial marker has highly interesting properties that 
warrant investigations in cancer patients. 
 1.  Introduction 
 Nanomaterials offer unique properties 
that can provide society with new health-
care technologies for treatment of disease. 
With the increasing aging of the popula-
tion in the western world, cancer inci-
dence continues to rise creating a crucial 
demand for effi cient and cost-effective 
therapies. Radiation therapy is a cost-effec-
tive treatment modality and approximately 
50% of cancer patients receive radia-
tion therapy after being diagnosed with 
cancer. [ 1 ] Modern radiation oncology relies 
on advanced, high-precision imaging tech-
niques such as computed tomography 
(CT), positron emission tomography 
(PET), and magnetic resonance (MR) to 
enable the delivery of high radiation doses 
to defi ned targets. [ 2–4 ] However, tumors 
rarely display a fi xed position during irra-
diation or within the treatment period 
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due to breathing motion, changes in organ fi lling, and tumor 
size. [ 5–7 ] To compensate for variations in tumor position fre-
quent imaging (kilovoltage radiographs or fl uoroscopy—also 
referred to as 2D X-ray imaging) during the course of treatment 
or image-guided radiation therapy (IGRT) is now being used in 
the clinic to improve radiation precision and accuracy, thereby 
reducing the treatment toxicity and optimizing therapeutic effi -
cacy. [ 2,6,8 ] When the tumor position cannot be correlated with 
internal reference points such as the skeleton, tumor localiza-
tion can be enhanced by alignment to radiographic markers 
implanted in or near the tumor. [ 9–11 ] Such markers can improve 
treatment through optimized planning, tumor positioning 
accuracy, and tumor tracking resulting in more precise dose 
delivery and enable treatment of cancers, which are presently 
not eligible for radiotherapy. [ 12,13 ] Tissue markers currently used 
in the clinic are metal-based solid implants with large physical 
dimensions, which require complicated insertion procedures 
and therefore the risk of complications. Lung tumor inser-
tion is especially problematic, with pneumothorax (reported 
in 33%–68% of patients) as well as bleeding being reported as 
primary complications. [ 14–16 ] In order to increase the usability 
and patient compliance of radiographic markers, we recently 
described the concept of a liquid injectable fi ducial marker by 
exploiting polyethylene glycol (PEG)-coated gold nanoparticles 
(AuNPs) in a nonsolvent-induced phase separation (NIPS) 
gelation matrix. [ 17 ] This system was found to be biocompatible 
and clearly visible on 3D X-ray imaging, However, due to the 
chemical properties of the encapsulated AuNPs only 10 mg 
AuNPs mL −1 providing approximately 200 Hounsfi eld units 
(HU) of contrast could be included, which is insuffi cient for 
2D X-ray visualization. For gating-based radiation procedures, 
often exploited in for example lung cancer patients, 2D X-ray 
visualization is required for intrafractional real-time imaging of 
moving tumors. [ 6,18–20 ] Additionally, fi ducial marker visualiza-
tion using 2D X-ray techniques lowers the X-ray exposure level 
to the patients and may reduce treatment time compared to 
3D X-ray-based procedures. [ 2 ] Furthermore, with the increasing 
focus on stereotactic radiation procedures and the clinical intro-
duction of proton therapy, visualization of tumor position and 
motion becomes crucial to optimize irradiation of cancerous 
tissue. [ 21,22 ] Therefore, radiopaque fi ducial markers continue to 
be in high demand and development of new marker systems is 
of paramount importance. 
 In the present work, we have investigated a novel liquid 
fi ducial marker (nanogel) system based on sucrose acetate 
isobutyrate (SAIB) and uniform poly( N -isopropyl acrylamide) 
(PNIPAM)-coated AuNPs with radio-opacity adequate for 2D 
X-ray visualization. SAIB, a fully acylated derivative of sucrose, 
is a biodegradable nonpolymeric compound, which has been 
approved for oral consumption and is generally regarded as safe 
(GRAS) by the FDA. SAIB mixtures with ethanol (EtOH) behaves 
as Newtonian liquids and have a low viscosity (50–200 mPa s) 
suited for injection using thin hypodermic needles. [ 23–25 ] Upon 
hydration, an amorphous (gel-like) solid is formed, which effi -
ciently encapsulate high concentrations (>100 mg Au mL −1 ) 
of PNIPAM-coated AuNPs providing contrast levels suffi cient 
for visualization in 2D X-ray imaging techniques such as 
fl uoroscopy and ExacTrac imaging (Brainlab AG, Feldkirchen, 
Germany). The developed nanogel has been characterized in 
vitro and the in vivo stability and visibility was evaluated in 
immunocompetent mice over a period of 8 weeks. Proof-of-
concept in a clinical canine cancer patient with a spontaneous 
growing tumor was additionally established and the developed 
nanogel with PNIPAM-coated AuNPs was applied in IGRT in 
a canine cancer patient where marker visibility, stability, and 
marker migration were evaluated over time during the course 
of radiotherapy. The developed nanogel fulfi lls the require-
ments for use in guidance of radiation therapy as it is easy to 
inject, remains stable over the full time course of radiation 
treatment (6 weeks), shows no sign of migration, and is the 
fi rst liquid fi ducial marker to enable visualization using both 
2D and 3D X-ray-based imaging techniques. 
 2.  Results and Discussion 
 Visualization of fi ducial markers in 2D X-ray imaging requires 
high electron density within the nanogel to possess effi -
cient X-ray attenuation/radio-opacity, which can be achieved 
by doping the injectable gel with colloid AuNPs. We recently 
exploited the use of PEG-coated AuNPs but due to the high 
hydrophilicity of the PEG-coated AuNPs only 10 mg AuNPs 
mL −1 could be included in the liquid marker, which was insuf-
fi cient for 2D X-ray visibility. Higher AuNP-concentrations 
resulted in a signifi cant burst release due to the higher prefer-
ence of the hydrophilic PEG-coated AuNPs for the surrounding 
aqueous phase. [ 17 ] 
 2.1.  Engineering AuNPs for Enhanced Nanogel Compatibility 
 In order to increase the concentration of AuNPs and enhance 
the compatibility of the AuNPs with the hydrophobic SAIB-
based gelation matrix, two different strategies were investi-
gated: i) Masking the AuNPs by chemisorption of a dithiolane 
SAIB derivate ((SH) 2 -SAIB) ( 5 ) (see Section 2.1.1, and Sup-
porting Information) and ii) using commercially available thiol-
functionalized PNIPAM with a molecular weight of 3.500 Da 
(SH-PNIPAM 3.500 ). Both strategies resulted in hydrophobic 
AuNPs, which was anticipated to reduce the previously 
observed AuNP burst release from the nanogels. Hence, we 
hypothesized that realization of one or both of these strategies 
should enable formulation of nanogels with higher concentra-
tions of AuNPs resulting in higher X-ray contrast levels. 
 2.1.1.  Synthesis of SAIB-Based Capping Agent for AuNP 
Functionalization 
 The dithiolane-functionalized SAIB derivate  5 was prepared as 
outlined in Scheme S1 (Supporting Information) starting from 
sucrose ( 1 ). Mono silyl protection of the 6′-OH position of the 
fructofuranose unit was achieved using  tert -butyl(chloro)diphe-
nylsilane (TBDPS-Cl) and 4-dimethylaminopyridine (DMAP) 
yielding 6′-O-TBDPS-sucrose ( 2 ). [ 26 ] The remaining hydroxyl 
groups were isobutyrylated using isobutyric anhydride and 
DMAP resulting hepta-isobutyryl-6′-O-TBDPS-sucrose ( 3 ). 
Initial attempts of deprotection of the TBDPS group using 
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 tetra - n -butylammonium fl uoride (TBAF) indicated a high 
degree of isobutyryl migration; fortunately, this could be sup-
pressed by addition of acetic acid leading to hepta-isobutyryl-
sucrose ( 4 ). Finally, the dithiolane moiety was introduced by 
 N -(3-dimethylaminopropyl)- N′ -ethylcarbodiimide (EDC) activa-
tion of lipoic acid in the presence of DMAP yielding the dithi-
olane-functionalized SAIB derivate  5 (a detailed description of 
synthesis and compound characterization is available as Sup-
porting Information). 
 2.1.2.  AuNP Synthesis, Functionalization, and Characterization 
 Citrate-stabilized AuNPs were synthesized using a seeding 
procedure as previously described resulting in uniform elec-
trostatic-stabilized AuNPs with a diameter of approximately 
40 nm. [ 17 ] Subsequently, chemisorption of SH-PEG 5000 , SH-
PNIPAM 3500 or (SH) 2 -SAIB ( 5 ) to the citrate-stabilized AuNPs 
was conducted in aqueous solution in order to increase the col-
loid compatibility with SAIB-based gels ( Figure  1 A). Increasing 
the compatibility of the AuNPs with the SAIB-matrix includes 
increasing the hydrophobicity of the particles. However, a deli-
cate balance exists where the hydrophobicity of the particles is 
increased without compromising their stability in aqueous solu-
tion during synthesis. As evident from the UV–vis (Figure  1 B) 
and dynamic light scattering (DLS) (Figure  1 C) analysis, AuNP 
coating with PEG and PNIPAM was successful. Only a slight 
increase in the surface plasmon resonance was observed, 
which is expected due to the microenvironmental changes on 
the surface of the particles. Additionally, DLS confi rmed the 
presence of the two polymers at the colloid interface since an 
increase of 15.1 and 12.9 nm was observed for the PEG-coated 
and PNIPAM-coated AuNPs, respectively. However, chem-
isorption of (SH) 2 -SAIB ( 5 ) to the surface of the electrostatic-
stabilized AuNPs caused considerably aggregation due to the 
poor aqueous solubility of the formed particles, even under 
the very diluted conditions used. The aggregates formed from 
SAIB-coated AuNPs were isolated but redispersion in organic 
solvents such as absolute ethanol was not possible; thus, this 
class of particles was not investigated further. Synthesis and 
 Figure 1.  A) Synthesis protocol for obtaining PEG-, PNIPAM, and SAIB-coated AuNPs based on a three steep seeding protocol using chloroauric acid as 
Au 3+ source and trisodium citrate as reductant and stabilizer; B) UV–vis characterization of PEG-, PNIPAM-, and SAIB-coated AuNPs in aqueous solu-
tion; C) DLS characterization of PEG-, PNIPAM-, and SAIB-coated AuNPs in aqueous solution; and D) ζ-potential characterization of PEG-, PNIPAM-, 
and SAIB-coated AuNPs in aqueous solution. E) Nanogel composition and preparation procedure.
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subsequently coating of AuNPs with (SH) 2 -SAIB ( 5 ) in pure 
organic solvent using the Burst–Shiffi n method may be fea-
sible, but this was not attempted due to the small size of 
particles formed by this method (<10 nm) and the fact that non-
biocompatible solvents such as toluene and toxic phase-transfer 
agents have to be used, which could limit their use in biological 
settings. [ 27 ] 
 Additionally, handling of PNIPAM-coated AuNPs was found 
to be superior compared to PEG-coated AuNPs as these could 
be lyophilized and stored for prolonged time as an air stabile 
nanopowder, which readily dispersed into MQ-H 2 O and a wide 
range of protic- and aprotic organic solvents including anhy-
drous ethanol without causing any changes to particle mor-
phology (Figure S1, Supporting Information). This enabled 
easy up-concentration, storage, and nanogel formulation com-
pared to the previous described method where AuNPs were 
transferred into anhydrous EtOH by centrifugation prior to use. 
 2.2.  Contrast Evaluation for 2D X-Ray Visualization of Nanogel 
in Humans 
 In order to evaluate the required concentration of AuNPs within 
the nanogel for visibility on 2D X-rays images in humans, a 
simulation of 2D digitally reconstructed radiographs (DRRs) 
was performed based on clinical 3D CT-data for a patient diag-
nosed with lung cancer. A lung tumor model was chosen as 
this region is considered as a worst-case scenario due to the 
high concentration of bone structure in the thoracic region. 
A simulated nanogel (500 µL) was digitally placed inside the 
lung tumor of the patient and the specifi ed HU contrast level 
was varied from 500 to 2000 HU with increments steps of 500 
HU on the 3D CT-data. 2D DRRs were created for all angles 
entering perpendicular around the patient in steps of 5° using 
a ray-tracing algorithm [ 28,29 ] resulting in 72 simulated projec-
tions for each contrast level ( Figure  2 ). The center position 
of the DRRs was chosen to be in the center of the simulated 
nanogel placed centrally within the lung tumor of the patient. 
On the resulting DRRs, the visibility for each contrast level was 
evaluated by a contrast-to-noise ratio (CNR) approach, where a 
region of interest (ROI) for one projection and contrast level 
was contoured to defi ne the nanogel and then transferred to all 
other projections. The mean intensity ( M m ) and standard devia-
tion ( σ m ) of ROIs were calculated and compared to the mean 
( M b ) and standard deviation ( σ b ) from a ROI on a DRR with 
no simulated nanogel present according to a CNR evaluation 
(Equation  ( 1) ).
 
M M
σ σ
=
−
−
CNR m b
m
2
b
2
 
 (1)
 
 The CNR level can be considered a quantitative measurement 
of the visibility of the object measured compared to the back-
ground contrast from the surroundings. Generally, high CNR 
translate to increased visibility of the marker. We considered 
the simulated nanogel visible in the 2D DRR if CNR > 2. This 
value corresponds to a signifi cance level of 0.05 obtained from 
a two-tailed  t -test with a large number of degrees-of-freedom. [ 30 ] 
As evident from Figure  2 , some angles requires a higher X-ray 
contrast level of the nanogel in order to obtain a CNR > 2 as 
these penetrates bone structure prior to reaching the nanogel. 
Other angles are more easily accessible and thereby result in 
lower background contrast, thus making the nanogel more vis-
ible on the 2D DRRs. Based on the lung cancer patient projec-
tion simulation on the DRRs, it was evident that the contrast 
level required for CNR > 2 in 95% of all perpendicular angles 
was approximately 1000 HU (spherical nanogel with a total 
volume of 500 µL) corresponding to a nanogel with approxi-
mately 30 mg AuNPs mL −1 . A comparison of the 2D X-ray 
contrast level from PNIPAM-coated AuNPs (10, 30, 60, and 
90 mg mL −1 ) and clinically used solid fi ducial markers is 
provided in Figure S2, Supporting Information. 
 2.3.  In Vitro Evaluation of Nanogel Performance 
 In vitro release kinetics of encapsulated PEG-coated and 
PNIPAM-coated AuNPs in SAIB nanogels doped with polylactic 
acid (PLA) with the composition SAIB/EtOH/PLA (75:20:5) + 
30 mg AuNPs mL −1 were examined by placing small droplets 
(200 µL) of nanogels into MQ-H 2 O at physiological tempera-
ture. Small aliquots of MQ-H 2 O were removed at specifi c time 
intervals and replaced with fresh MQ-H 2 O to mimic the sink 
effect in vivo. The amount of released AuNPs was determined 
by UV–vis spectroscopy using a standard curve of individual 
synthesized and coated AuNPs with a known concentration 
(Figure S3, Supporting Information). Injection of nanogel into 
aqueous solution causes an effl ux of EtOH from the nanogel 
into the aqueous compartment. Effl ux of EtOH results in rapid 
increase in gel viscosity, [ 24 ] but may also induce a burst release 
of encapsulated AuNPs. [ 24 ] Indeed, a rapid burst release of PEG-
coated AuNPs from nanogels composed of SAIB/EtOH/PLA 
(75:20:5) + 30 mg PEG-coated AuNPs mL −1 was observed. In 
contrast, the use of PNIPAM-coated AuNPs resulted in highly 
stable nanogels with no (<1%) AuNP release over time in vitro 
despite the high AuNP concentration in the gel (Figure S3, 
Supporting Information). Concentrations as high as 100 mg 
PNIPAM-coated AuNPs mL −1 were evaluated without induced 
burst release of encapsulated PNIPAM-coated AuNPs (data not 
shown). The enhanced compatibility of the PNIPAM-coated 
AuNPs with the SAIB matrix compared to the PEG-coated 
counterpart can be explained by the enhanced hydropho-
bicity and potential hydrogen bonding interactions between 
Adv. Healthcare Mater. 2015, 4, 856–863
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 Figure 2.  Contrast to noise (CNR) level versus angle of entrance for a 
simulated nanogel (500 µL) with various contrast levels (500–2000 HU) 
placed digitally inside a lung tumor.
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the PNIPAM-coating polymers and the polyester backbone of 
SAIB. The positive in vitro stability results and known target 
AuNP concentration for 2D X-ray visibility encouraged us to 
further evaluate the nanogels composed of SAIB/EtOH/PLA 
(75:20:5) + 30 mg PNIPAM-coated AuNPs mL −1 in vivo using 
immunocompetent mice. 
 2.4.  In Vivo Evaluation of Nanogel Performance 
 2.4.1.  Evaluation of Nanogel in Immunocompetent Healthy 
NMRI-Mice 
 Nanogels (200 µL) composed of SAIB/EtOH/PLA (75:20:5) + 
30 mg PNIPAM-coated AuNPs mL −1 were injected subcutane-
ously in immunocompetent NMRI-mice ( n = 5) at the upper left 
fl ank using a 25G needle under general anesthesia. The nanogel 
was visualized using micro-CT imaging over a period of 8 weeks 
(images acquired directly after injection and again after 24, 48 h, 
1, 2, 4, and 8 weeks) using a dedicated small-animal scanner 
( Figure  3 ). Based on the recorded micro-CT images, the nanogel 
X-ray contrast level, degradation rate, and homogeneity were eval-
uated as a function of time ( Figure  4 ). No signifi cant changes in the 
nanogel volume were observed after the initial EtOH effl ux phase, 
which caused approximately 20% reduction of nanogel volume in 
good correlation with the known EtOH content of the nanogel 
prior to injection. The nanogel doped with 30 mg PNIPAM-
coated AuNPs mL −1 provided a mean X-ray contrast level in the 
range of 1200 HU, which is suffi cient for 2D X-ray visualization 
as previously described. A reduction of the mean contrast level of 
the nanogel was observed over time possible due to some AuNP 
leakage or aggregation of particles within the nanogel. Figure  4 B 
clearly displays the increased maximum contrast level within 
the nanogel during the fi rst week following intra-gel AuNP 
aggregation resulting in very high contrast levels (>15.000 HU) 
(Figure S4, Supporting Information). The homogeneity of the 
nanogel in terms of PNIPAM-coated AuNP distribution within 
the gel matrix was analyzed further by investigating each voxel 
of the micro-CT images as illustrated in Figure  4 C. As evident 
from the cumulative histograms for a representative mouse, the 
PNIPAM-coated AuNPs were found to gradually aggregate within 
the nanogel as previously observed for PEG-coated AuNPs within 
the same gel matrix. [ 17 ] In fact, no signifi cant difference was found 
in the variance of the PEG-coated and PNIPAM-coated AuNPs 
within the nanogels as analyzed by the Wilcoxon rank-sum test 
( p = 0.0734). [ 31 ] The inhomogeneous PNIPAM-coated AuNPs 
distribution within the nanogel could be visualized in the mice 
due to the high resolution and small slice thickness (0.092 × 
0.092 × 0.092 mm 3 ) of the micro-CT scanner. The aggregation 
phenomenon of the PNIPAM-coated AuNPs within the nanogel 
has no clinical impact as human clinical scanners operate with 
signifi cant larger slice thickness (2–3 mm) and lower resolution 
(1 × 1 mm 2 ) causing the AuNP microstructure aggregation to be 
below the resolution of recorded images. 
 2.4.2.  Evaluation of Nanogel in a Canine Cancer Patient with 
Spontaneously Developed Solid Tumor 
 In order to fully validate the concept of liquid injectable fi du-
cial markers for IGRT, the nanogel was evaluated in a canine 
cancer patient suffering from spontaneously developed malig-
nant solid tumor (mast cell tumor). Solid tumors often show 
an increased interstitial fl uid pressure (IFP) possibly due to 
vessel abnormalities, fi brosis, and contraction of the intersti-
tial matrix mediated by stromal fi broblasts. [ 32,33 ] Increased IFP 
may serve as an obstacle for intratumoral injection of the devel-
oped nanogel as the available intracellular space for marker 
assembly post-injection is limited and the increased IFP may 
repel the nanogel into adjacent areas. Additionally, migration of 
the nanogel over time may compromise the accuracy of fi ducial 
Adv. Healthcare Mater. 2015, 4, 856–863
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 Figure 3.  Representative 3D reconstruction from micro-CT images of 
mouse. Nanogel composed of SAIB/EtOH/PLA (75:20:5) + 30 mg PNIPAM-
coated AuNPs mL −1 administered subcutaneously to immunocompetent 
mice at the upper left fl ank. Nanogel visualized from different angles.
 Figure 4.  In vivo characteristics of nanogel composed of SAIB/EtOH/PLA (75:20:5) + 30 mg PNIPAM-coated AuNPs mL −1 administered subcutane-
ously to immunocompetent mice at the upper left fl ank. A) Nanogel degradation over a period of 8 weeks (mean ± SEM,  n = 5); B) Mean (left axis) 
and maximum (right axis) X-ray contrast level of nanogel over a period of 8 weeks (mean ± SEM,  n = 5) and C) Accumulated histogram of nanogel 
contrast level within each pixel from a representative mouse over a period of 30 d.
FU
LL P
A
P
ER
861wileyonlinelibrary.com© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
marker-based IGRT and potentially result in misguidance of 
the external radiation beam, which, in turn, leads to poor tumor 
coverage and increased radiation to healthy adjacent tissue. [ 16,34 ] 
Such obstacles are not encountered for subcutaneous injections 
of the nanogel as evaluated in immunocompetent NMRI-mice, 
hence the canine cancer patient with a spontaneously devel-
oped solid tumor (mast cell tumor) served as a clinical animal 
model with high translational value for evaluating the clinical 
potential of the developed nanogel. 
 A companion dog (Male, Rhodesian Ridgeback, 10 years, 
body weight 38 kg) diagnosed with a subcutaneous mast cell 
tumor (maximum distance ( x ×  y ×  z ); 1.82 × 5.81 × 5.32 cm 3 , 
CT volume; 31.64 cm 3 ) adherent to the underlying soft tissue 
located over the dorsal aspect of the left shoulder blade was 
given an intratumoral injection of nanogel (300 µL) composed 
of SAIB/EtOH/PLA (75:20:5) + 30 mg PNIPAM-coated AuNPs 
mL −1 under general anesthesia ( Figure  5 ) prior to radiation 
therapy. Approximately 24 h after the injection of the nanogel, a 
diagnostic planning CT-scan of the tumor/nanogel region was 
performed and the therapeutic regimen consisting of four frac-
tions of 6 Gy radiation therapy planned accordingly. Radiation 
therapy was delivered over 16 d on a clinical linear accelerator 
equipped with on-board imaging (OBI) capabilities (3D cone 
beam CT (CBCT) and 2D X-ray imaging). 
 Prior to each fraction of radiotherapy, CBCT ( Figure  6 ) 
images and 2D X-ray imaging  ( Figure S5, Supporting Informa-
tion) were acquired and used for positioning based on nanogel 
and tumor. Radiation therapy was delivered according to the 
nanogel position. The size ( Table  1 ) and stability of the nanogel 
in terms of migration and deformation were evaluated based on 
the recorded CBCT images (Figure  6 ) by manually contouring 
the nanogel using 300 HU as a lower threshold. The nanogel 
size remained constant over the time of treatment with no 
change in overall volume was observed. The small variations 
observed in Table  1 are a consequence of motion artifacts from 
respiratory movement on the recorded CBCT images. Addition-
ally, image analysis revealed that the nanogel retained its 3D 
shape and was found to be immobilized/associated with the 
tumor as no migration of the nanogel was observed during 
the course of radiation therapy despite the canine patient exer-
cising and resting on the tumor inducing mechanical stress on 
the nanogel. Finally, exposure to four fractions of 6 Gy each was 
not found to alter the nanogel morphology as evaluated based 
on the CBCT images. The nanogel was well tolerated and no 
clinical side effects were observed throughout the study. 
 3.  Conclusion 
 A novel nanogel composition based on PNIPAM-coated AuNPs 
formulated in a mixture of SAIB/EtOH/PLA (70:20:5) has been 
developed. PNIPAM-coated AuNPs were found to be highly 
compatible with the hydrophobic SAIB-based gel matrix facili-
tating encapsulation of high concentration of colloidal gold, 
which enables 2D X-ray visualization of the nanogel. This was 
confi rmed by a simulation of 2D DRRs of a patient suffering 
from lung cancer. The developed nanogel is the fi rst inject-
able fi ducial marker that can be visualized in 2D X-ray imaging 
thereby enabling intra- and interfractional IGRT by referencing 
the nanogel position. The nanogel performance was evaluated 
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 Figure 5.  3D reconstruction based on CT images of canine patient with injected nanogel. Nanogel composed of SAIB/EtOH/PLA (75:20:5) + 30 mg PNIPAM-
coated AuNPs mL −1 administered intratumorally into a canine suffering from an intermediate-grade subcutaneous mast cell tumor (maximum distance 
( x ×  y ×  z ); 1.82 × 5.81 × 5.32 cm 3 , CT volume; 31.64 cm 3 ) adherent to the underlying soft tissue located over the dorsal aspect of the left shoulder blade. 
A) Full-body scan of the canine. Area of interest indicated with a red box. B–D) Nanogel visualized from different angles.
 Figure 6.  Nanogel composed of SAIB/EtOH/PLA (75:20:5) + 30 mg PNIPAM-coated AuNPs mL −1 administered intratumorally into a canine mast 
cell tumor visualized by CBCT imaging. A) Transversal plane (day 0); B) frontal plane (day 0); C) sagittal plane (day 0). Contours in A–C represent the 
nanogel on day 6 (green), day 9 (yellow), day 13 (blue), and day 16 (red). The light blue contour represents the gross tumor volume. D) 3D renderings 
of all the four surfaces represent the nanogel from each day of treatment.
FU
LL
 P
A
P
ER
862 wileyonlinelibrary.com © 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
in vivo in immunocompetent mice by subcutaneous injection. 
Excellent visibility of the nanogel by micro-CT imaging was 
observed with a mean contrast level of 1200 HU after injec-
tion. Over time, the PNIPAM-coated AuNPs were found to 
form microaggregates within the gel matrix as confi rmed by 
image analysis of the high-resolution micro-CT images. This 
phenomenon was found to have no clinical impact due to the 
larger slice thickness of human clinical scanners and lower res-
olution compared to small animal micro-CT scanners. 
 The concept of an injectable fi ducial marker for use in IGRT 
was fi nally validated in a canine cancer patient with a large spon-
taneous solid tumor. The canine patient provides translational 
understanding and allowed us to evaluate the clinical potential 
of the nanogel. The nanogel displayed high image contrast on 
both conventional CT and CBCT images and could addition-
ally be identifi ed by 2D X-ray imaging, thus providing suffi cient 
radiographic properties for visualization with all the imaging 
modalities associated with modern linear accelerators. Further-
more, the nanogel retained its size and 3D structure within 
the tumor microenvironment and no migration of the nanogel 
was observed within the time period for the radiotherapy treat-
ment procedure. The developed nanogel was utilized to align 
the canine patient prior to external beam radiation therapy, was 
found to be unaffected by the deposited radiation dose within the 
tumor, and no side effects were observed in neither the murine 
nor the clinically relevant canine model. However, it should be 
noted that AuNPs are currently not approved for human use and 
the knowledge about the potential short- and long-term toxico-
logical effects after AuNP exposure is still limited. [ 36 ] 
 The developed nanogel presented in this article is the fi rst 
liquid fi ducial marker, which can be inserted using thin and 
fl exible needles and with a high enough contrast to make it vis-
ible in 2D X-ray imaging, which is an important feature for use 
in IGRT. Furthermore, active pharmaceutical ingredients may 
be included in the nanogel formulation to improve the thera-
peutic benefi t for the patient, and the AuNPs may enhance 
the effect of the radiation therapy if the gel is injected directly 
into tumors. [ 37,38 ] In conclusion, the nanogel may provide both 
human and veterinary radiation oncologists with a new tool for 
improving planning, alignment, and tumor tracking in radio-
therapy and could improve treatment outcome by providing a 
more precise delivery of the radiation dose to tumors. 
 4.  Experimental Section 
 Materials : Tetrachloroauric acid trihydrate was purchased from Wako 
Chemicals GmbH (Neuss, Germany) and MeO-PEG 5000 -SH was purchased 
from Rapp Polymere (Tuebingen, Germany). SH-PNIPAM ( M w = 3500Da, 
PDI = 1.24) was purchased from Polymer Source Inc. (Dorval, Canada). 
All other chemicals including SAIB, PLA ( M w = 10–18 kDa), trisodium 
citrate dihydrate, Au-standard for inductively coupled plasma atomic 
emission spectroscopy (ICP-AES) (1000 mg L −1 ), hydrochloride acid and 
nitric acid were purchased from Sigma–Aldrich (Schnelldorf, Germany). 
All chemicals were used as received from the manufacturer. 
 Synthesis of (SH) 2 -SAIB ( 5 ) : (SH) 2 -SAIB ( 5 ) was synthesized over four 
steps starting from sucrose ( 1 ) in an overall yield of 27%. Full synthetic 
procedure including chemical characterization ( 1 H NMR,  13 C NMR, 
HRMS, and FTIR) is available in the Supporting Information. 
 AuNP Synthesis and Characterization : AuNPs were synthesized as 
previously described using a two-step seeding procedure resulting 
in citrate-stabilized AuNPs with an average diameter of 40 nm. [ 17 ] 
The citrate-stabilized AuNPs were subsequently coated with either 
SH-PEG 5000 , SH-PNIPAM 3500, or (SH) 2 -SAIB ( 5 ) using eight molecules 
per nm 2 surface area. Chemisorption of coating materials was in all 
cases conducted overnight at RT after which the volume was reduced 
to approximately 15 mL by centrifugation (9.500 RPM, 15 min). The 
PEG-coated AuNPs, PNIPAM-coated AuNPs, and SAIB-coated AuNPs 
colloid solutions were washed with MQ-H 2 O (3 × 15 mL) and the 
fi nally up-concentrated to approximately 75 mg Au mL −1 as determined 
by ICP-MS using an ICP-MS Au standard (1000 mg L −1 ) as reference. 
Colloid solutions (citrate-stabilized AuNPs, PEG-, PNIPAM-, and SAIB-
coated AuNPs) were furthermore characterized by UV–vis spectrometry, 
DLS, and ζ-potential measured. PNIPAM-coated AuNPs were fi nally 
characterized by TEM (Figure S2, Supporting Information). 
 Nanogel Formulation : SAIB (1.75 g, 90 w/w% in EtOH) and PLA 
(105 mg) were mixed and homogenized by a ball homogenizer 
(frequency 30 s −1 , 30 min) to give a clear homogenous solution. 
Lyophilized PNIPAM-coated AuNPs (63 mg) was weighed off and 
redispersed into anhydrous EtOH (310 µL) by extensive vortexing and 
added to the SAIB/PLA mixture to give a fi nal nanogel forming matrix 
composed of SAIB/EtOH/PLA (75:20:5) with 3.0 w/w% (30 mg mL −1 ) 
PNIPAM-coated AuNPs. Formed nanogels were stored at RT and used 
within 4 h from preparation with vortexing prior to use. Nanogels with 
PEG-coated AuNPs were prepared as described elsewhere. [ 17 ] 
 In Vitro Release of PNIPAM -  and PEG -Coated  AuNPs from Nanogel : 
Nanogels composed of SAIB/EtOH/PLA (75:20:5) with 3.0 w/w% 
(30.0 mg mL −1 ) of either PEG- or PNIPAM-coated AuNPs were prepared 
as described above. Nanogels (200 µL) were added to glass vials 
containing MQ-H 2 O (10.0 mL, 37 °C) and aliquots (1.0 mL) were removed 
as a function of time and replaced with an equal amount of MQ-H 2 O. 
The release profi le from both nanogels was measured by correlating the 
UV–vis absorbance of the individual AuNPs with a standard curve based 
on Au-standards of known concentration (5.0–50.0 µg mL −1 ). 
 Simulation of CNR in Lung Cancer Patient : 2D DRRs were performed 
based on clinical 3D CT-data for a patient diagnosed with lung cancer. 2D 
DRRs were created using the drrCode ray-tracing algorithm available online 
(https://code.google.com/p/drrsuite/downloads/list). 2D DRRs were 
created using a source to detector distance of 150 cm and a detector size of 
768 × 1024 pixels (identical to a clinical settings). For conversion from HU to 
attenuation coeffi cient, a μρ for water was used assuming monochromatic 
photons of 120 kV. ROI contouring and CNR calculations for the simulated 
projections were performed in MATLAB (The MathWorks Inc., Natick, MA, 
USA) using an in-house-developed simulation and analysis tool. 
 Animal Models (Mice) : Immunocompetent 7-week-old female NMRI 
mice ( n = 5) were given a subcutaneous injection (200 µL) of SAIB/
EtOH/PLA (75:20:5) + 30 mg mL −1 PNIPAM-coated AuNPs using 
a 25 G needle in the upper left fl ank of the anesthetized mice. The 
animals were given free access to food and water and micro-CT scans 
were recorded over a period of 8 weeks (24, 48 h, 1, 2, 4, and 8 weeks) 
using a dedicated small-animal MicroCAT II system (Siemens Medical 
Solutions, Malvern, PA, USA). Micro-CT images were recorded using 
the following settings; tube voltage of 67 kVp, tube current of 500 µA, 
360 rotation steps, an exposure time of 400 ms, and a voxel size of 
0.092 × 0.092 × 0.092 mm 3 . The animal experiments were approved by 
the Animal Research Committee of the Danish Ministry of Justice. 
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 Table 1.  Nanogel volume following intratumoral injection in a canine 
model. 
Day # Nanogel volume [cm 3 ]
0 0.20
6 0.18
9 0.21
13 0.22
16 0.19
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 Canine : A privately owned companion dog (Male, Rhodesian 
Ridgeback, 10 years, bodyweight 38 kg) suffering from a spontaneously 
developed subcutaneous mast cell tumor (maximum distance 
( x ×  y ×  z ); 1.82 × 5.81 × 5.32 cm 3 , CT volume; 31.64 cm 3 ) adherent 
to the underlying soft tissue located over the dorsal aspect of the left 
shoulder blade was used as a clinical relevant model. In conjunction 
with the standard diagnostic procedures, nanogel (300 µL) was manually 
injected centrally in the tumor using a 23 G needle and 1 mL syringe. 
Approximately 24 h after the injection of the nanogel, a diagnostic CT 
scan (Biograph 40, Siemens Medical Solutions, Erlangen, Germany) of 
the tumor region was performed with the dog under general anesthesia 
using the following acquisition parameters; 120 kV, 150 mAs, pixel 
size 0.977 × 0.977 × 1.00 mm 3 ). As part of the therapeutic procedure 
radiation therapy was planned according to the tumor histology and 
imaging characteristic, and a therapeutic regimen consisting of four 
fractions of 6 Gy radiation treatments was chosen. Radiation therapy was 
delivered by a linear accelerator (Novalis TX, Varian Medical Systems, 
Palo Alto, CA, USA) with on-board imaging capabilities (Cone Beam CT 
and 2D X-ray imaging) and orthogonal ExacTrac radiography (Brainlab 
AG, Feldkirchen, Germany). No side effects were observed throughout 
the study. The canine cancer patient study was approved by the Ethics 
and Administrative Committee at the Department of Veterinary Clinical 
and Animal Sciences, Faculty of Health and Medical Sciences, University 
of Copenhagen, Denmark. 
 Analysis of Nanogel Homogeneity : The nanogels were delineated by 
hand using ITK-SNAP. [ 35 ] All data analyses were done in MATLAB (The 
MathWorks Inc., Natick, MA, USA) using in-house- developed software. 
Based on the voxel values in the gels mean and max values, as well as 
cumulative histograms were calculated. The cumulative histograms were 
used for homogeneity evaluation, as changes in the AuNP distribution 
are refl ected in the voxels values and thus the histograms. 
 Supporting Information 
 Supporting Information is available from the Wiley Online Library or 
from the author. 
 Acknowledgements 
 This work has been funded by the Technical University of Denmark 
(DTU), the Niels Bohr Institute, the Danish Council for Strategic Research 
(Nanoguide , application no. 0603-00442B), and the Novo Foundation. 
Received:  October 17, 2014 
Revised:  December 3, 2014 
Published online: January 21, 2015 
[1]  R.  Baskar ,  K. A.  Lee ,  R.  Yeo ,  K.  Yeoh ,  Int. J. Med. Sci.  2012 ,  9 ,  193 . 
[2]  L. A.  Dawson ,  M. B.  Sharpe ,  Lancet Oncol.  2006 ,  7 ,  848 . 
[3]  J.  Bussink ,  J. H. A. M.  Kaanders ,  W. T.  A. van der Graaf , 
 W. J. G.  Oyen ,  Nat. Rev. Clin. Oncol.  2011 ,  8 ,  233 . 
[4]  D.  Verellen ,  R. M.  De ,  N.  Linthout ,  K.  Tournel ,  G.  Soete ,  G.  Storme , 
 Nat. Rev. Cancer  2007 ,  7 ,  949 . 
[5]  K. M.  Langen ,  D. T.  Jones ,  Int. J. Radiat. Oncol. Biol. Phys.  2001 ,  50 ,  265 . 
[6]  H.  Shirato ,  Y.  Seppenwoolde ,  K.  Kitamura ,  R.  Onimura ,  S.  Shimizu , 
 Semin. Radiat. Oncol.  2004 ,  14 ,  10 . 
[7]  P.  Giraud ,  E.  Yorke ,  S.  Jiang ,  L.  Simon ,  K.  Rosenzweig ,  G.  Mageras , 
 Cancer Radiother.  2006 ,  10 ,  269 . 
[8]  M.  Falk ,  P. M.  af Rosenschold ,  P.  Keall ,  H.  Cattell ,  B. C.  Cho , 
 P.  Poulsen ,  S.  Povzner ,  A.  Sawant ,  J.  Zimmerman ,  S.  Korreman , 
 Radiother. Oncol.  2010 ,  94 ,  218 . 
[9]  D. P.  Harley ,  W. S.  Krimsky ,  S.  Sarkar ,  D.  Highfi eld ,  C.  Aygun , 
 B.  Gurses ,  Ann. Thorac. Surg.  2010 ,  89 ,  368 . 
[10]  M.  Imura ,  K.  Yamazaki ,  H.  Shirato ,  R.  Onimaru ,  M.  Fujino , 
 S.  Shimizu ,  T.  Harada ,  S.  Ogura ,  H.  Dosaka-Akita ,  K.  Miyasaka , 
 M.  Nishimura ,  Int. J. Radiat. Oncol. Biol. Phys.  2005 ,  63 ,  1442 . 
[11]  D. J.  Moseley ,  E. A.  White ,  K. L.  Wiltshire ,  T.  Rosewall ,  M. B.  Sharpe , 
 J. H.  Siewerdsen ,  J.  Bissonnette ,  M.  Gospodarowicz ,  P.  Warde , 
 C. N.  Catton ,  D. A.  Jaffray ,  Int. J. Radiat. Oncol. Biol. Phys.  2007 ,  67 , 
 942 . 
[12]  I.  Gauthier ,  J.  Carrier ,  D.  Beliveau-Nadeau ,  B.  Fortin ,  D.  Taussky ,  Int. 
J. Radiat. Oncol. Biol. Phys.  2009 ,  74 ,  1128 . 
[13]  R.  Khosa ,  S.  Nangia ,  K. S.  Chufal ,  D.  Ghosh ,  R.  Kaul ,  L.  Sharma , 
 J. Cancer Res. Ther.  2010 ,  6 ,  172 . 
[14]  S.  Yousefi  ,  B. T.  Collins ,  C. A.  Reichner ,  E. D.  Anderson , 
 C.  Jamis-Dow ,  G.  Gagnon ,  S.  Malik ,  B.  Marshall ,  T.  Chang , 
 F.  Banovac ,  Clin. Lung Cancer  2007 ,  8 ,  252 . 
[15]  N.  Kothary ,  J. J.  Heit ,  J. D.  Louie ,  W. T.  Kuo ,  B. W. J.  Loo ,  A.  Koong , 
 D. T.  Chang ,  D.  Hovsepian ,  D. Y.  Sze ,  L. V.  Hofmann ,  J. Vasc. Interv. 
Radiol.  2009 ,  20 ,  235 . 
[16]  N.  Bhagat ,  N.  Fidelman ,  J. C.  Durack ,  J.  Collins ,  R. L.  Gordon , 
 J. M.  LaBerge ,  R. K. J.  Kerlan ,  Cardiovasc. Interv. Radiol.  2010 ,  33 ,  1186 . 
[17]  R. I.  Jølck ,  T.  Binderup ,  A. E.  Hansen ,  J. B.  Scherman , 
 P. M.  af Rosenschold ,  A.  Kjær ,  T. L.  Andresen ,  Adv. Healthcare 
Mater.  2014 ,  3 ,  1680 . 
[18]  H.  Shirato ,  K.  Suzuki ,  G. C.  Sharp ,  K.  Fujita ,  R.  Onimaru , 
 M.  Fujino ,  N.  Kato ,  Y.  Osaka ,  R.  Kinoshita ,  H.  Taguchi ,  S.  Onodera , 
 K.  Miyasaka ,  Int. J. Radiat. Oncol. Biol. Phys.  2006 ,  64 ,  1229 . 
[19]  T.  Juhler-Nottrup ,  S. S.  Korreman ,  A. N.  Pedersen ,  G. F.  Persson , 
 L. R.  Aarup ,  H.  Nystrom ,  M.  Olsen ,  N.  Tarnavski ,  L.  Specht ,  Acta 
Oncol.  2008 ,  47 ,  1406 . 
[20]  S. S.  Korreman ,  T.  Juhler-Nottrup ,  G. F.  Persson ,  P. A.  Navrsted , 
 M.  Enmark ,  H.  Nystrom ,  L.  Specht ,  Acta Oncol.  2008 ,  47 ,  1390 . 
[21]  M. L.  Taylor ,  T.  Kron ,  R. D.  Franich ,  Acta Oncol.  2011 ,  50 ,  483 . 
[22]  C.  Rubio ,  O.  Hernando ,  R.  Morera ,  T.  Leroy ,  S. E.  Lartigau ,  Rep. 
Pract. Oncol. Radiother.  2013 ,  18 ,  387 . 
[23]  Y.  Lu ,  H.  He ,  Y.  Cui ,  X.  Tang ,  Yao Xue Xue Bao.  2007 ,  42 ,  445 . 
[24]  Y.  Lu ,  Y.  Yu ,  X.  Tang ,  J. Pharm. Sci.  2007 ,  96 ,  3252 . 
[25]  X.  Lin ,  S.  Yang ,  J.  Gou ,  M.  Zhao ,  Y.  Zhang ,  N.  Qi ,  H.  He ,  C.  Cai , 
 X.  Tang ,  P.  Guo ,  J. Mater. Sci.: Mater. Med.  2012 ,  23 ,  443 . 
[26]  M. M.  Andrade ,  M. T.  Barros ,  Tetrahedron  2004 ,  60 ,  9235 . 
[27]  M.  Brust ,  M.  Walker ,  D.  Bethell ,  D. J.  Schiffrin ,  R.  Whyman ,  Chem. 
Commun.  1994 ,  7 ,  801 . 
[28]  F.  Jacobs ,  E.  Sundermann ,  B.  De Sutter ,  M.  Christiaens , 
 I.  Lemahieu ,  J .Comput. Inf. Technol.  1998 ,  6 ,  89 . 
[29]  R. L.  Siddon ,  Phys. Med. Biol.  1985 ,  30 ,  817 . 
[30]  Y.  Chen ,  J. J.  O’Connell ,  C. J.  Ko ,  R. R.  Mayer ,  A.  Belard , 
 J. E.  McDonough ,  Phys. Med. Biol.  2012 ,  57 ,  155 . 
[31]  F.  Wilcoxon ,  J. Econ. Entomol.  1946 ,  39 ,  269 . 
[32]  C.  Heldin ,  K.  Rubin ,  K.  Pietras ,  A.  Oestman ,  Nat. Rev. Cancer  2004 , 
 4 ,  806 . 
[33]  P.  Vaupel ,  Semin. Radiat. Oncol.  2004 ,  14 ,  198 . 
[34]  J. C.  Hong ,  N. C. W.  Eclov ,  Y.  Yu ,  A. K.  Rao ,  S.  Dieterich ,  Q.  Le , 
 M.  Diehn ,  D. Y.  Sze ,  B. W.  Loo Jr .,  N.  Kothary ,  P. G.  Maxim ,  J. Appl. 
Clin. Med. Phys.  2013 ,  14 ,  4046 . 
[35]  P. A.  Yushkevich ,  J.  Piven ,  H. C.  Hazlett ,  R. G.  Smith ,  S.  Ho , 
 J. C.  Gee ,  G.  Gerig ,  Neuroimage  2006 ,  31 ,  1116 . 
[36]  A.  Gerber ,  M.  Bundschuh ,  D.  Klingelhofer ,  D. A.  Groneberg , 
 J. Occup. Med. Toxicol.  2013 ,  8 ,  32 . 
[37]  X.  Zhang ,  D.  Wu ,  X.  Shen ,  J.  Chen ,  Y.  Sun ,  P.  Liu ,  X.  Liang ,  Biomate-
rials  2012 ,  33 ,  6408 . 
[38]  X.  Zhang ,  J.  Chen ,  Z.  Luo ,  D.  Wu ,  X.  Shen ,  S.  Song ,  Y.  Sun ,  P.  Liu , 
 J.  Zhao ,  S.  Huo ,  S.  Fan ,  F.  Fan ,  X.  Liang ,  J.  Xie ,  Adv. Healthcare 
Mater.  2014 ,  3 ,  133 . 
Adv. Healthcare Mater. 2015, 4, 856–863
www.advhealthmat.de
www.MaterialsViews.com
